Ex Vivo Soluble Fas Ligand Treatment of Donor Cells to Selectively Reduce Murine Acute Graft Versus Host Disease

被引：0
|
作者：
Georgantas, Robert W. [1 ]
Bohana-Kashtan, Osnat [1 ]
Civin, Curt I. [1 ,2 ]
机构：
[1] Johns Hopkins, Div Immunol & Hematopoiesis, Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA
来源：
MOLECULAR THERAPY | 2006年 / 13卷
关键词：
D O I：
10.1016/j.ymthe.2006.08.1137
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
1041
引用
收藏
页码：S399 / S399
页数：1
相关论文
共 50 条
  • [1] Ex vivo soluble Fas ligand treatment of donor cells to selectively reduce murine acute craft versus host disease
    Georgantas, Robert W., III
    Bohana-Kashtan, Osnat
    Civin, Curt I.
    TRANSPLANTATION, 2006, 82 (04) : 471 - 478
  • [2] Selective Reduction of Graft-versus-Host Disease-Mediating Human T Cells by Ex Vivo Treatment with Soluble Fas Ligand
    Bohana-Kashtan, Osnat
    Morisot, Sebastien
    Hildreth, Richard
    Brayton, Cory
    Levitsky, Hyam I.
    Civin, Curt I.
    JOURNAL OF IMMUNOLOGY, 2009, 183 (01): : 696 - 705
  • [3] Engineering Donor Lymphocytes with Fas Ligand as an Effective Approach to Prevent Acute Graft-Versus-Host Disease
    Turan, A.
    Shrestha, P.
    Batra, L.
    Arguc, F. N.
    Gulen, A.
    Shirwan, H.
    Yolcu, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S511 - S512
  • [4] Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease
    Shrestha, Pradeep
    Turan, Ali
    Batra, Lalit
    Gulen, Ayse Ece
    Sun, Zhengda
    Tan, Helen
    Askenasy, Nadir
    Shirwan, Haval
    Yolcu, Esma S.
    BLOOD ADVANCES, 2023, 7 (10) : 2181 - 2195
  • [5] Elimination of acute GvHD by ex vivo soluble Fas Ligand treatment of allo-reactive T cells
    Georgantas, R
    Malehorn, M
    Tanavde, V
    Straley, E
    Whartenby, K
    Civin, C
    EXPERIMENTAL HEMATOLOGY, 2003, 31 (07) : 83 - 83
  • [6] Ex vivo Fas ligand treatment selectively eliminates T cells that mediate GVHD.
    Kashtan, Osnat
    Levitsky, Hyam I.
    Civin, Curt I.
    BLOOD, 2006, 108 (11) : 904A - 904A
  • [7] Treatment with Mesenchymal Stromal Cells Overexpressing Fas-Ligand Ameliorates Acute Graft-versus-Host Disease in Mice
    Vacaru, Andrei Mircea
    Mazilu, Ana-Maria
    Dumitrescu, Madalina
    Fenyo, Ioana Madalina
    Gafencu, Anca Violeta
    Vacaru, Ana-Maria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (01)
  • [8] Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease
    Yolcu, Esma S.
    Kaminitz, Ayelet
    Mizrahi, Keren
    Ash, Shifra
    Yaniv, Isaac
    Stein, Jerry
    Shirwan, Haval
    Askenasy, Nadir
    EXPERIMENTAL HEMATOLOGY, 2013, 41 (10) : 903 - 911
  • [9] Differential use of Fas ligand and perforin effector pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia.
    van den Brink, MRM
    Horndasch, KJ
    Teshima, T
    Ferrara, JLM
    Burakoff, SJ
    BLOOD, 1999, 94 (10) : 324A - 324A
  • [10] The ex vivo toll-like receptor 7 tolerance induction in donor lymphocytes prevents murine acute graft-versus-host disease
    Zogas, Nikolaos
    Karponi, Garyfalia
    Iordanidis, Fotios
    Malasidis, Stylianos
    Paraskevas, Vasilios
    Papadopoulou, Anastasia
    Scouras, Zaharias George
    Anagnostopoulos, Achilles
    Yannaki, Evangelia
    CYTOTHERAPY, 2018, 20 (01) : 149 - 164
12345